37 results on '"White, Elizabeth B."'
Search Results
2. Evaluation of Plasma Biomarkers to Predict Major Adverse Kidney Events in Hospitalized Patients With COVID-19
- Author
-
Deng, Jie, Atta, Mo, Bagnasco, Serena M., Ko, Albert, Iwasaki, Akiko, Farhadian, Shelli, Nelson, Allison, Casanovas-Massana, Arnau, White, Elizabeth B., Schulz, Wade, Coppi, Andreas, Young, Patrick, Nunez, Angela, Shepard, Denise, Matos, Irene, Strong, Yvette, Anastasio, Kelly, Brower, Kristina, Kuang, Maxine, Chiorazzi, Michael, Bermejo, Santos, Vijayakumar, Pavithra, Geng, Bertie, Fournier, John, Minasyan, Maksym, Muenker, M. Catherine, Moore, Adam J., Nadkarni, Girish, Menez, Steven, Coca, Steven G., Moledina, Dennis G., Wen, Yumeng, Chan, Lili, Thiessen-Philbrook, Heather, Obeid, Wassim, Garibaldi, Brian T., Azeloglu, Evren U., Ugwuowo, Ugochukwu, Sperati, C. John, Arend, Lois J., Rosenberg, Avi Z., Kaushal, Madhurima, Jain, Sanjay, Wilson, F. Perry, and Parikh, Chirag R.
- Published
- 2023
- Full Text
- View/download PDF
3. High Influenza Incidence and Disease Severity Among Children and Adolescents Aged <18 Years--United States, 2022-23 Season
- Author
-
White, Elizabeth B., O'Halloran, Alissa, Sundaresan, Devi, Gilmer, Matthew, Threlkel, Ryan, Colon, Arielle, Tastad, Katie, Chai, Shua J., Alden, Nisha B., Yousey-Hindes, Kimberly, Openo, Kyle P., Ryan, Patricia A., Kim, Sue, Lynfield, Ruth, Spina, Nancy, Tesini, Brenda L., Martinez, Marc, Schmidt, Zachary, Sutton, Melissa, Talbot, H. Keipp, Hill, Mary, Biggerstaff, Matthew, Budd, Alicia, Garg, Shikha, Reed, Carrie, Iuliano, A. Danielle, and Bozio, Catherine H.
- Subjects
United States. Department of Health and Human Services ,Children -- Diseases ,Vaccination ,Antiviral agents ,Influenza vaccines ,Influenza ,Health ,Council of State and Territorial Epidemiologists - Abstract
Introduction During the 2022-23 season, influenza activity in the United States began in early October, earlier than in most previous seasons, and returned to pre-COVID-19 levels (1). In addition, high [...]
- Published
- 2023
4. Multiple Transmission Chains within COVID-19 Cluster, Connecticut, USA, 2020
- Author
-
Bart, Stephen M., Flaherty, Eileen, Alpert, Tara, Carlson, Sherry, Fasulo, Lisa, Earnest, Rebecca, White, Elizabeth B., Dickens, Noel, Brito, Anderson F., Grubaugh, Nathan D., Hadler, James L., and Sosa, Lynn E.
- Subjects
Disease transmission -- Genetic aspects ,Fitness (Genetics) -- Health aspects ,Company distribution practices ,Health - Abstract
During widespread community transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), transmission chains are sometimes unclear. Although often unavailable, viral genome sequencing can complement epidemiologic investigations. In fall 2020, [...]
- Published
- 2021
- Full Text
- View/download PDF
5. SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity
- Author
-
Anastasio, Kelly, Askenase, Michael H., Batsu, Maria, Bickerton, Sean, Brower, Kristina, Bucklin, Molly L., Cahill, Staci, Cao, Yiyun, Courchaine, Edward, DeIuliis, Giuseppe, Earnest, Rebecca, Geng, Bertie, Goldman-Israelow, Benjamin, Handoko, Ryan, Khoury-Hanold, William, Kim, Daniel, Knaggs, Lynda, Kuang, Maxine, Lapidus, Sarah, Lim, Joseph, Linehan, Melissa, Lu-Culligan, Alice, Martin, Anjelica, Matos, Irene, McDonald, David, Minasyan, Maksym, Nakahata, Maura, Naushad, Nida, Nouws, Jessica, Obaid, Abeer, Odio, Camila, Oh, Ji Eun, Omer, Saad, Park, Annsea, Park, Hong-Jai, Peng, Xiaohua, Petrone, Mary, Prophet, Sarah, Rice, Tyler, Rose, Kadi-Ann, Sewanan, Lorenzo, Sharma, Lokesh, Shaw, Albert C., Shepard, Denise, Smolgovsky, Mikhail, Sonnert, Nicole, Strong, Yvette, Todeasa, Codruta, Valdez, Jordan, Velazquez, Sofia, Vijayakumar, Pavithra, White, Elizabeth B., Yang, Yexin, Vogels, Chantal B.F., Watkins, Anne E., Harden, Christina A., Brackney, Doug E., Shafer, Jared, Wang, Jianhui, Caraballo, César, Kalinich, Chaney C., Ott, Isabel M., Fauver, Joseph R., Kudo, Eriko, Lu, Peiwen, Venkataraman, Arvind, Tokuyama, Maria, Moore, Adam J., Muenker, M. Catherine, Casanovas-Massana, Arnau, Fournier, John, Bermejo, Santos, Campbell, Melissa, Datta, Rupak, Nelson, Allison, Dela Cruz, Charles S., Ko, Albert I., Iwasaki, Akiko, Krumholz, Harlan M., Matheus, J.D., Hui, Pei, Liu, Chen, Farhadian, Shelli F., Sikka, Robby, Wyllie, Anne L., and Grubaugh, Nathan D.
- Published
- 2021
- Full Text
- View/download PDF
6. Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT–qPCR primer–probe sets
- Author
-
Vogels, Chantal B. F., Brito, Anderson F., Wyllie, Anne L., Fauver, Joseph R., Ott, Isabel M., Kalinich, Chaney C., Petrone, Mary E., Casanovas-Massana, Arnau, Catherine Muenker, M., Moore, Adam J., Klein, Jonathan, Lu, Peiwen, Lu-Culligan, Alice, Jiang, Xiaodong, Kim, Daniel J., Kudo, Eriko, Mao, Tianyang, Moriyama, Miyu, Oh, Ji Eun, Park, Annsea, Silva, Julio, Song, Eric, Takahashi, Takehiro, Taura, Manabu, Tokuyama, Maria, Venkataraman, Arvind, Weizman, Orr-El, Wong, Patrick, Yang, Yexin, Cheemarla, Nagarjuna R., White, Elizabeth B., Lapidus, Sarah, Earnest, Rebecca, Geng, Bertie, Vijayakumar, Pavithra, Odio, Camila, Fournier, John, Bermejo, Santos, Farhadian, Shelli, Dela Cruz, Charles S., Iwasaki, Akiko, Ko, Albert I., Landry, Marie L., Foxman, Ellen F., and Grubaugh, Nathan D.
- Published
- 2020
- Full Text
- View/download PDF
7. Early and Increased Influenza Activity Among Children--Tennessee, 2022-23 Influenza Season
- Author
-
Thomas, Christine M., White, Elizabeth B., Kojima, Noah, Fill, Mary-Margaret A., Hanna, Samir, Jones, Timothy F., Newhouse, Caitlin N., Orejuela, Kelly, Roth, Emma, Winders, Sarah, Chandler, Daniel R., Grijalva, Carlos G., Schaffner, William, Schmitz, Jonathan E., DaSilva, Juliana, Kirby, Marie K., Mellis, Alexandra M., Rolfes, Melissa A., Sumner, Kelsey M., Flannery, Brendan, Talbot, H. Keipp, and Dunn, John R.
- Subjects
United States. Department of Health and Human Services ,Medical research ,Medicine, Experimental ,Pediatrics ,Genomics ,Influenza viruses ,Influenza ,Health ,Vanderbilt University. Medical Center - Abstract
Influenza seasons typically begin in October and peak between December and February (1); however, the 2022-23 influenza season in Tennessee began in late September and was characterized by high pediatric [...]
- Published
- 2023
8. Evaluation of Plasma Biomarkers to Predict Major Adverse Kidney Events in Hospitalized Patients With COVID-19
- Author
-
Menez, Steven, primary, Coca, Steven G., additional, Moledina, Dennis G., additional, Wen, Yumeng, additional, Chan, Lili, additional, Thiessen-Philbrook, Heather, additional, Obeid, Wassim, additional, Garibaldi, Brian T., additional, Azeloglu, Evren U., additional, Ugwuowo, Ugochukwu, additional, Sperati, C. John, additional, Arend, Lois J., additional, Rosenberg, Avi Z., additional, Kaushal, Madhurima, additional, Jain, Sanjay, additional, Wilson, F. Perry, additional, Parikh, Chirag R., additional, Deng, Jie, additional, Atta, Mo, additional, Bagnasco, Serena M., additional, Ko, Albert, additional, Iwasaki, Akiko, additional, Farhadian, Shelli, additional, Nelson, Allison, additional, Casanovas-Massana, Arnau, additional, White, Elizabeth B., additional, Schulz, Wade, additional, Coppi, Andreas, additional, Young, Patrick, additional, Nunez, Angela, additional, Shepard, Denise, additional, Matos, Irene, additional, Strong, Yvette, additional, Anastasio, Kelly, additional, Brower, Kristina, additional, Kuang, Maxine, additional, Chiorazzi, Michael, additional, Bermejo, Santos, additional, Vijayakumar, Pavithra, additional, Geng, Bertie, additional, Fournier, John, additional, Minasyan, Maksym, additional, Muenker, M. Catherine, additional, Moore, Adam J., additional, and Nadkarni, Girish, additional
- Published
- 2023
- Full Text
- View/download PDF
9. Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons--43 U.S. Jurisdictions, July 31-October 1, 2022
- Author
-
Payne, Amanda B., Ray, Logan C., Cole, Matthew M., Canning, Michelle, Houck, Kennedy, Shah, Hazel J., Farrar, Jennifer L., Lewis, Nathaniel M., Fothergill, Amy, White, Elizabeth B., Feldstein, Leora R., Roper, Lauren E., Lee, Florence, Kriss, Jennifer L., Sims, Emily, Spicknall, Ian H., Nakazawa, Yoshinori, Gundlapalli, Adi V., Shimabukuro, Tom, Cohen, Adam L., Honein, Margaret A., Mermin, Jonathan, and Payne, Daniel C.
- Subjects
United States. Food and Drug Administration ,Jurisdiction ,Drug approval ,Vaccines ,Health - Abstract
As of October 28, 2022, a total of 28,244 * monkeypox (mpox) cases have been reported in the United States during an outbreak that has disproportionately affected gay, bisexual, and [...]
- Published
- 2022
10. Incidence of Monkeypox Among Unvaccinated Persons Compared with Persons Receiving >1 JYNNEOS Vaccine Dose--32 U.S. Jurisdictions, July 31-September 3, 2022
- Author
-
Payne, Amanda B., Ray, Logan C., Kugeler, Kiersten J., Fothergill, Amy, White, Elizabeth B., Canning, Michelle, Farrar, Jennifer L., Feldstein, Leora R., Gundlapalli, Adi V., Houck, Kennedy, Kriss, Jennifer L., Lewis, Nathaniel M., Sims, Emily, Smith, Dawn K., Spicknall, Ian H., Nakazawa, Yoshinori, Damon, Inger K., Cohn, Amanda C., and Payne, Daniel C.
- Subjects
United States. Food and Drug Administration ,Human monkeypox ,Jurisdiction ,Vaccines ,Health - Abstract
On September 30, 2022, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr). Human monkeypox is caused by Monkeypox virus (MPXV), an Orthopoxvirus, previously rare [...]
- Published
- 2022
11. Is aggregated surveillance data a reliable method for constructing tuberculosis care cascades? A secondary data analysis from Uganda
- Author
-
White, Elizabeth B., primary, Hernández-Ramírez, Raúl U., additional, Majwala, Robert Kaos, additional, Nalugwa, Talemwa, additional, Reza, Tania, additional, Cattamanchi, Adithya, additional, Katamba, Achilles, additional, and Davis, J. Lucian, additional
- Published
- 2022
- Full Text
- View/download PDF
12. Incidence of Monkeypox Among Unvaccinated Persons Compared with Persons Receiving ≥1 JYNNEOS Vaccine Dose — 32 U.S. Jurisdictions, July 31–September 3, 2022
- Author
-
Payne, Amanda B., primary, Ray, Logan C., additional, Kugeler, Kiersten J., additional, Fothergill, Amy, additional, White, Elizabeth B., additional, Canning, Michelle, additional, Farrar, Jennifer L., additional, Feldstein, Leora R., additional, Gundlapalli, Adi V., additional, Houck, Kennedy, additional, Kriss, Jennifer L., additional, Lewis, Nathaniel M., additional, Sims, Emily, additional, Smith, Dawn K., additional, Spicknall, Ian H., additional, Nakazawa, Yoshinori, additional, Damon, Inger K., additional, Cohn, Amanda C., additional, and Payne, Daniel C., additional
- Published
- 2022
- Full Text
- View/download PDF
13. Prognostic Significance of Urinary Biomarkers in Patients Hospitalized With COVID-19
- Author
-
Menez, Steven, primary, Moledina, Dennis G., additional, Thiessen-Philbrook, Heather, additional, Wilson, F. Perry, additional, Obeid, Wassim, additional, Simonov, Michael, additional, Yamamoto, Yu, additional, Corona-Villalobos, Celia P., additional, Chang, Crystal, additional, Garibaldi, Brian T., additional, Clarke, William, additional, Farhadian, Shelli, additional, Dela Cruz, Charles, additional, Coca, Steven G., additional, Parikh, Chirag R., additional, Ko, Albert, additional, Iwasaki, Akiko, additional, Nelson, Allison, additional, Casanovas-Massana, Arnau, additional, White, Elizabeth B., additional, Schulz, Wade, additional, Coppi, Andreas, additional, Young, Patrick, additional, Nunez, Angela, additional, Shepard, Denise, additional, Matos, Irene, additional, Strong, Yvette, additional, Anastasio, Kelly, additional, Brower, Kristina, additional, Kuang, Maxine, additional, Chiorazzi, Michael, additional, Bermejo, Santos, additional, Vijayakumar, Pavithra, additional, Geng, Bertie, additional, Fournier, John, additional, Minasyan, Maksym, additional, Muenker, M. Catherine, additional, Moore, Adam J., additional, and Nadkarni, Girish, additional
- Published
- 2022
- Full Text
- View/download PDF
14. Sex differences in immune responses that underlie COVID-19 disease outcomes
- Author
-
Takahashi, Takehiro, Ellingson, Mallory K., Wong, Patrick, Israelow, Benjamin, Lucas, Carolina, Klein, Jon, Silva, Julio, Mao, Tianyang, Oh, Ji Eun, Tokuyama, Maria, Lu, Peiwen, Venkataraman, Arvind, Park, Annsea, Liu, Feimei, Meir, Amit, Sun, Jonathan, Wang, Eric Y., Casanovas-Massana, Arnau, Wyllie, Anne L., Vogels, Chantal B. F., Earnest, Rebecca, Lapidus, Sarah, Ott, Isabel M., Moore, Adam J., Anastasio, Kelly, Askenase, Michael H., Batsu, Maria, Beatty, Hannah, Bermejo, Santos, Bickerton, Sean, Brower, Kristina, Bucklin, Molly L., Cahill, Staci, Campbell, Melissa, Cao, Yiyun, Courchaine, Edward, Datta, Rupak, DeIuliis, Giuseppe, Geng, Bertie, Glick, Laura, Handoko, Ryan, Kalinich, Chaney, Khoury-Hanold, William, Kim, Daniel, Knaggs, Lynda, Kuang, Maxine, Kudo, Eriko, Lim, Joseph, Linehan, Melissa, Lu-Culligan, Alice, Malik, Amyn A., Martin, Anjelica, Matos, Irene, McDonald, David, Minasyan, Maksym, Mohanty, Subhasis, Muenker, M. Catherine, Naushad, Nida, Nelson, Allison, Nouws, Jessica, Nunez-Smith, Marcella, Obaid, Abeer, Ott, Isabel, Park, Hong-Jai, Peng, Xiaohua, Petrone, Mary, Prophet, Sarah, Rahming, Harold, Rice, Tyler, Rose, Kadi-Ann, Sewanan, Lorenzo, Sharma, Lokesh, Shepard, Denise, Silva, Erin, Simonov, Michael, Smolgovsky, Mikhail, Song, Eric, Sonnert, Nicole, Strong, Yvette, Todeasa, Codruta, Valdez, Jordan, Velazquez, Sofia, Vijayakumar, Pavithra, Wang, Haowei, Watkins, Annie, White, Elizabeth B., Yang, Yexin, Shaw, Albert, Fournier, John B., Odio, Camila D., Farhadian, Shelli, Dela Cruz, Charles, Grubaugh, Nathan D., Schulz, Wade L., Ring, Aaron M., Ko, Albert I., Omer, Saad B., and Iwasaki, Akiko
- Subjects
0301 basic medicine ,Multidisciplinary ,Innate immune system ,biology ,business.industry ,T cell ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,medicine.anatomical_structure ,Immune system ,Immunity ,030220 oncology & carcinogenesis ,Immunology ,biology.protein ,Medicine ,Antibody ,business ,Viral load ,Sex characteristics ,Cohort study - Abstract
There is increasing evidence that coronavirus disease 2019 (COVID-19) produces more severe symptoms and higher mortality among men than among women1-5. However, whether immune responses against severe acute respiratory syndrome coronavirus (SARS-CoV-2) differ between sexes, and whether such differences correlate with the sex difference in the disease course of COVID-19, is currently unknown. Here we examined sex differences in viral loads, SARS-CoV-2-specific antibody titres, plasma cytokines and blood-cell phenotyping in patients with moderate COVID-19 who had not received immunomodulatory medications. Male patients had higher plasma levels of innate immune cytokines such as IL-8 and IL-18 along with more robust induction of non-classical monocytes. By contrast, female patients had more robust T cell activation than male patients during SARS-CoV-2 infection. Notably, we found that a poor T cell response negatively correlated with patients' age and was associated with worse disease outcome in male patients, but not in female patients. By contrast, higher levels of innate immune cytokines were associated with worse disease progression in female patients, but not in male patients. These findings provide a possible explanation for the observed sex biases in COVID-19, and provide an important basis for the development of a sex-based approach to the treatment and care of male and female patients with COVID-19.
- Published
- 2020
15. Health Care Utilization Before and After the “Muslim Ban” Executive Order Among People Born in Muslim-Majority Countries and Living in the US
- Author
-
Samuels, Elizabeth A., primary, Orr, Lilla, additional, White, Elizabeth B., additional, Saadi, Altaf, additional, Padela, Aasim I., additional, Westerhaus, Michael, additional, Bhatt, Aarti D., additional, Agrawal, Pooja, additional, Wang, Dennis, additional, and Gonsalves, Gregg, additional
- Published
- 2021
- Full Text
- View/download PDF
16. SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity
- Author
-
Vogels, Chantal B.F., primary, Watkins, Anne E., additional, Harden, Christina A., additional, Brackney, Doug E., additional, Shafer, Jared, additional, Wang, Jianhui, additional, Caraballo, César, additional, Kalinich, Chaney C., additional, Ott, Isabel M., additional, Fauver, Joseph R., additional, Kudo, Eriko, additional, Lu, Peiwen, additional, Venkataraman, Arvind, additional, Tokuyama, Maria, additional, Moore, Adam J., additional, Muenker, M. Catherine, additional, Casanovas-Massana, Arnau, additional, Fournier, John, additional, Bermejo, Santos, additional, Campbell, Melissa, additional, Datta, Rupak, additional, Nelson, Allison, additional, Dela Cruz, Charles S., additional, Ko, Albert I., additional, Iwasaki, Akiko, additional, Krumholz, Harlan M., additional, Matheus, J.D., additional, Hui, Pei, additional, Liu, Chen, additional, Farhadian, Shelli F., additional, Sikka, Robby, additional, Wyllie, Anne L., additional, Grubaugh, Nathan D., additional, Anastasio, Kelly, additional, Askenase, Michael H., additional, Batsu, Maria, additional, Bickerton, Sean, additional, Brower, Kristina, additional, Bucklin, Molly L., additional, Cahill, Staci, additional, Cao, Yiyun, additional, Courchaine, Edward, additional, DeIuliis, Giuseppe, additional, Earnest, Rebecca, additional, Geng, Bertie, additional, Goldman-Israelow, Benjamin, additional, Handoko, Ryan, additional, Khoury-Hanold, William, additional, Kim, Daniel, additional, Knaggs, Lynda, additional, Kuang, Maxine, additional, Lapidus, Sarah, additional, Lim, Joseph, additional, Linehan, Melissa, additional, Lu-Culligan, Alice, additional, Martin, Anjelica, additional, Matos, Irene, additional, McDonald, David, additional, Minasyan, Maksym, additional, Nakahata, Maura, additional, Naushad, Nida, additional, Nouws, Jessica, additional, Obaid, Abeer, additional, Odio, Camila, additional, Oh, Ji Eun, additional, Omer, Saad, additional, Park, Annsea, additional, Park, Hong-Jai, additional, Peng, Xiaohua, additional, Petrone, Mary, additional, Prophet, Sarah, additional, Rice, Tyler, additional, Rose, Kadi-Ann, additional, Sewanan, Lorenzo, additional, Sharma, Lokesh, additional, Shaw, Albert C., additional, Shepard, Denise, additional, Smolgovsky, Mikhail, additional, Sonnert, Nicole, additional, Strong, Yvette, additional, Todeasa, Codruta, additional, Valdez, Jordan, additional, Velazquez, Sofia, additional, Vijayakumar, Pavithra, additional, White, Elizabeth B., additional, and Yang, Yexin, additional
- Published
- 2021
- Full Text
- View/download PDF
17. Longitudinal analyses reveal immunological misfiring in severe COVID-19
- Author
-
Lucas, Carolina, Wong, Patrick, Klein, Jon, Castro, Tiago B. R., Silva, Julio, Sundaram, Maria, Ellingson, Mallory K., Mao, Tianyang, Oh, Ji Eun, Israelow, Benjamin, Takahashi, Takehiro, Tokuyama, Maria, Lu, Peiwen, Venkataraman, Arvind, Park, Annsea, Mohanty, Subhasis, Wang, Haowei, Wyllie, Anne L., Vogels, Chantal B. F., Earnest, Rebecca, Lapidus, Sarah, Ott, Isabel M., Moore, Adam J., Muenker, M. Catherine, Fournier, John B., Campbell, Melissa, Odio, Camila D., Casanovas-Massana, Arnau, Obaid, Abeer, Lu-Culligan, Alice, Nelson, Allison, Brito, Anderson, Nunez, Angela, Martin, Anjelica, Watkins, Annie, Geng, Bertie, Kalinich, Chaney, Harden, Christina, Todeasa, Codruta, Jensen, Cole, Kim, Daniel, McDonald, David, Shepard, Denise, Courchaine, Edward, White, Elizabeth B., Song, Eric, Silva, Erin, Kudo, Eriko, DeIuliis, Giuseppe, Rahming, Harold, Park, Hong-Jai, Matos, Irene, Nouws, Jessica, Valdez, Jordan, Fauver, Joseph, Lim, Joseph, Rose, Kadi-Ann, Anastasio, Kelly, Brower, Kristina, Glick, Laura, Sharma, Lokesh, Sewanan, Lorenzo, Knaggs, Lynda, Minasyan, Maksym, Batsu, Maria, Petrone, Mary, Kuang, Maxine, Nakahata, Maura, Linehan, Melissa, Askenase, Michael H., Simonov, Michael, Smolgovsky, Mikhail, Sonnert, Nicole, Naushad, Nida, Vijayakumar, Pavithra, Martinello, Rick, Datta, Rupak, Handoko, Ryan, Bermejo, Santos, Prophet, Sarah, Bickerton, Sean, Velazquez, Sofia, Alpert, Tara, Rice, Tyler, Khoury-Hanold, William, Peng, Xiaohua, Yang, Yexin, Cao, Yiyun, Strong, Yvette, Herbst, Roy, Shaw, Albert C., Medzhitov, Ruslan, Schulz, Wade L., Grubaugh, Nathan D., Dela Cruz, Charles, Farhadian, Shelli, Ko, Albert I., Omer, Saad B., and Iwasaki, Akiko
- Subjects
Adult ,Male ,0301 basic medicine ,Chemokine ,T-Lymphocytes ,medicine.medical_treatment ,T cell ,Pneumonia, Viral ,Disease ,Article ,Pathogenesis ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Cluster Analysis ,Humans ,Medicine ,Pandemics ,Aged ,Aged, 80 and over ,Interleukin-13 ,Innate immune system ,Multidisciplinary ,biology ,business.industry ,COVID-19 ,Immunoglobulin E ,Middle Aged ,Viral Load ,Eosinophils ,030104 developmental biology ,Cytokine ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Interleukin 13 ,Immunology ,biology.protein ,Cytokines ,Female ,Interleukin-5 ,Coronavirus Infections ,business - Abstract
Recent studies have provided insights into the pathogenesis of coronavirus disease 2019 (COVID-19)1–4. However, the longitudinal immunological correlates of disease outcome remain unclear. Here we serially analysed immune responses in 113 patients with moderate or severe COVID-19. Immune profiling revealed an overall increase in innate cell lineages, with a concomitant reduction in T cell number. An early elevation in cytokine levels was associated with worse disease outcomes. Following an early increase in cytokines, patients with moderate COVID-19 displayed a progressive reduction in type 1 (antiviral) and type 3 (antifungal) responses. By contrast, patients with severe COVID-19 maintained these elevated responses throughout the course of the disease. Moreover, severe COVID-19 was accompanied by an increase in multiple type 2 (anti-helminths) effectors, including interleukin-5 (IL-5), IL-13, immunoglobulin E and eosinophils. Unsupervised clustering analysis identified four immune signatures, representing growth factors (A), type-2/3 cytokines (B), mixed type-1/2/3 cytokines (C), and chemokines (D) that correlated with three distinct disease trajectories. The immune profiles of patients who recovered from moderate COVID-19 were enriched in tissue reparative growth factor signature A, whereas the profiles of those with who developed severe disease had elevated levels of all four signatures. Thus, we have identified a maladapted immune response profile associated with severe COVID-19 and poor clinical outcome, as well as early immune signatures that correlate with divergent disease trajectories.
- Published
- 2020
- Full Text
- View/download PDF
18. The Impact of the “Muslim Ban” Executive Order on Healthcare Utilization in Minneapolis-St. Paul, Minnesota
- Author
-
Samuels, Elizabeth A., primary, Orr, Lilla, additional, White, Elizabeth B., additional, Saadi, Altaf, additional, Padela, Aasim I., additional, Westerhaus, Michael, additional, Bhatt, Aarti D., additional, Agrawal, Pooja, additional, Wang, Dennis, additional, and Gonsalves, Gregg, additional
- Published
- 2020
- Full Text
- View/download PDF
19. 456. Implementing an At-Home Smell Test for Early Assessment of COVID-19 in High-Risk Healthcare Workers
- Author
-
Weiss, Julian J, primary, Attuquayefio, Tuki, additional, White, Elizabeth B, additional, Geng, Bertie, additional, Handoko, Ryan, additional, Herz, Rachel S, additional, White, Theresa L, additional, Iwasaki, Akiko, additional, Grubaugh, Nathan D, additional, Datta, Rupak, additional, Campbell, Melissa, additional, Martinello, Richard A, additional, Ko, Albert I, additional, Small, Dana M, additional, and Farhadian, Shelli F, additional
- Published
- 2020
- Full Text
- View/download PDF
20. Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2
- Author
-
Wyllie, Anne L., primary, Fournier, John, additional, Casanovas-Massana, Arnau, additional, Campbell, Melissa, additional, Tokuyama, Maria, additional, Vijayakumar, Pavithra, additional, Warren, Joshua L., additional, Geng, Bertie, additional, Muenker, M. Catherine, additional, Moore, Adam J., additional, Vogels, Chantal B.F., additional, Petrone, Mary E., additional, Ott, Isabel M., additional, Lu, Peiwen, additional, Venkataraman, Arvind, additional, Lu-Culligan, Alice, additional, Klein, Jonathan, additional, Earnest, Rebecca, additional, Simonov, Michael, additional, Datta, Rupak, additional, Handoko, Ryan, additional, Naushad, Nida, additional, Sewanan, Lorenzo R., additional, Valdez, Jordan, additional, White, Elizabeth B., additional, Lapidus, Sarah, additional, Kalinich, Chaney C., additional, Jiang, Xiaodong, additional, Kim, Daniel J., additional, Kudo, Eriko, additional, Linehan, Melissa, additional, Mao, Tianyang, additional, Moriyama, Miyu, additional, Oh, Ji E., additional, Park, Annsea, additional, Silva, Julio, additional, Song, Eric, additional, Takahashi, Takehiro, additional, Taura, Manabu, additional, Weizman, Orr-El, additional, Wong, Patrick, additional, Yang, Yexin, additional, Bermejo, Santos, additional, Odio, Camila D., additional, Omer, Saad B., additional, Dela Cruz, Charles S., additional, Farhadian, Shelli, additional, Martinello, Richard A., additional, Iwasaki, Akiko, additional, Grubaugh, Nathan D., additional, and Ko, Albert I., additional
- Published
- 2020
- Full Text
- View/download PDF
21. Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs
- Author
-
Wyllie, Anne L., primary, Fournier, John, additional, Casanovas-Massana, Arnau, additional, Campbell, Melissa, additional, Tokuyama, Maria, additional, Vijayakumar, Pavithra, additional, Geng, Bertie, additional, Muenker, M. Catherine, additional, Moore, Adam J., additional, Vogels, Chantal B.F., additional, Petrone, Mary E., additional, Ott, Isabel M., additional, Lu, Peiwen, additional, Venkataraman, Arvind, additional, Lu-Culligan, Alice, additional, Klein, Jonathan, additional, Earnest, Rebecca, additional, Simonov, Michael, additional, Datta, Rupak, additional, Handoko, Ryan, additional, Naushad, Nida, additional, Sewanan, Lorenzo R., additional, Valdez, Jordan, additional, White, Elizabeth B., additional, Lapidus, Sarah, additional, Kalinich, Chaney C., additional, Jiang, Xiaodong, additional, Kim, Daniel J., additional, Kudo, Eriko, additional, Linehan, Melissa, additional, Mao, Tianyang, additional, Moriyama, Miyu, additional, Oh, Ji Eun, additional, Park, Annsea, additional, Silva, Julio, additional, Song, Eric, additional, Takahashi, Takehiro, additional, Taura, Manabu, additional, Weizman, Orr-El, additional, Wong, Patrick, additional, Yang, Yexin, additional, Bermejo, Santos, additional, Odio, Camila, additional, Omer, Saad B., additional, Dela Cruz, Charles S., additional, Farhadian, Shelli, additional, Martinello, Richard A., additional, Iwasaki, Akiko, additional, Grubaugh, Nathan D., additional, and Ko, Albert I., additional
- Published
- 2020
- Full Text
- View/download PDF
22. Analytical sensitivity and efficiency comparisons of SARS-COV-2 qRT-PCR primer-probe sets
- Author
-
Vogels, Chantal B.F., primary, Brito, Anderson F., additional, Wyllie, Anne L., additional, Fauver, Joseph R., additional, Ott, Isabel M., additional, Kalinich, Chaney C., additional, Petrone, Mary E., additional, Casanovas-Massana, Arnau, additional, Muenker, M. Catherine, additional, Moore, Adam J., additional, Klein, Jonathan, additional, Lu, Peiwen, additional, Lu-Culligan, Alice, additional, Jiang, Xiaodong, additional, Kim, Daniel J., additional, Kudo, Eriko, additional, Mao, Tianyang, additional, Moriyama, Miyu, additional, Oh, Ji Eun, additional, Park, Annsea, additional, Silva, Julio, additional, Song, Eric, additional, Takahashi, Takehiro, additional, Taura, Manabu, additional, Tokuyama, Maria, additional, Venkataraman, Arvind, additional, Weizman, Orr-El, additional, Wong, Patrick, additional, Yang, Yexin, additional, Cheemarla, Nagarjuna R., additional, White, Elizabeth B., additional, Lapidus, Sarah, additional, Earnest, Rebecca, additional, Geng, Bertie, additional, Vijayakumar, Pavithra, additional, Odio, Camila, additional, Fournier, John, additional, Bermejo, Santos, additional, Farhadian, Shelli, additional, Dela Cruz, Charles S., additional, Iwasaki, Akiko, additional, Ko, Albert I., additional, Landry, Marie L., additional, Foxman, Ellen F., additional, and Grubaugh, Nathan D., additional
- Published
- 2020
- Full Text
- View/download PDF
23. The Impact of the “Muslim Ban” Executive Order on Healthcare Utilization in Minneapolis-St. Paul, Minnesota
- Author
-
Samuels, Elizabeth Anne, primary, Orr, Lilla, additional, White, Elizabeth B., additional, Saadi, Altaf, additional, Padela, Aasim I., additional, Westerhaus, Michael, additional, Bhatt, Aarti D., additional, Agrawal, Pooja, additional, Wang, Dennis, additional, and Gonsalves, Gregg, additional
- Published
- 2020
- Full Text
- View/download PDF
24. The disposition of SS-looted victim gold durnig and after World War II.
- Author
-
White, Elizabeth B.
- Subjects
World War II, 1939-1945 ,Looting -- History ,Money laundering -- History ,Restitution and indemnification claims (1933- ) -- History - Published
- 1999
25. Multiple Transmission Chains within COVID-19 Cluster, Connecticut, USA, 20201.
- Author
-
Bart, Stephen M., Flaherty, Eileen, Alpert, Tara, Carlson, Sherry, Fasulo, Lisa, Earnest, Rebecca, White, Elizabeth B., Dickens, Noel, Brito, Anderson F., Grubaugh, Nathan D., Hadler, James L., and Sosa, Lynn E.
- Subjects
COVID-19 ,SARS-CoV-2 ,PHYSICAL fitness centers ,RESPIRATORY infections - Abstract
In fall 2020, a coronavirus disease cluster comprising 16 cases occurred in Connecticut, USA. Epidemiologic and genomic evidence supported transmission among persons at a school and fitness center but not a workplace. The multiple transmission chains identified within this cluster highlight the necessity of a combined investigatory approach. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. Feasibility, Acceptability, and Adoption of Digital Fingerprinting During Contact Investigation for Tuberculosis in Kampala, Uganda: A Parallel-Convergent Mixed-Methods Analysis
- Author
-
White, Elizabeth B, primary, Meyer, Amanda J, additional, Ggita, Joseph M, additional, Babirye, Diana, additional, Mark, David, additional, Ayakaka, Irene, additional, Haberer, Jessica E, additional, Katamba, Achilles, additional, Armstrong-Hough, Mari, additional, and Davis, John Lucian, additional
- Published
- 2018
- Full Text
- View/download PDF
27. Tracking smell loss to identify healthcare workers with SARS-CoV-2 infection.
- Author
-
Weiss, Julian J., Attuquayefio, Tuki N., White, Elizabeth B., Li, Fangyong, Herz, Rachel S., White, Theresa L., Campbell, Melissa, Geng, Bertie, Datta, Rupak, Wyllie, Anne L., Grubaugh, Nathan D., Casanovas-Massana, Arnau, Muenker, M. Catherine, Moore, Adam J., Handoko, Ryan, Iwasaki, Akiko, Martinello, Richard A., Ko, Albert I., Small, Dana M., and Farhadian, Shelli F.
- Subjects
MEDICAL personnel ,SARS-CoV-2 ,COVID-19 ,SMELL ,BEHAVIORAL assessment ,POLYMERASE chain reaction - Abstract
Introduction: Healthcare workers (HCW) treating COVID-19 patients are at high risk for infection and may also spread infection through their contact with vulnerable patients. Smell loss has been associated with SARS-CoV-2 infection, but it is unknown whether monitoring for smell loss can be used to identify asymptomatic infection among high risk individuals. In this study we sought to determine if tracking smell sensitivity and loss using an at-home assessment could identify SARS-CoV-2 infection in HCW. Methods and findings: We performed a prospective cohort study tracking 473 HCW across three months to determine if smell loss could predict SARS-CoV-2 infection in this high-risk group. HCW subjects completed a longitudinal, behavioral at-home assessment of olfaction with household items, as well as detailed symptom surveys that included a parosmia screening questionnaire, and real-time quantitative polymerase chain reaction testing to identify SARS-CoV-2 infection. Our main measures were the prevalence of smell loss in SARS-CoV-2-positive HCW versus SARS-CoV-2-negative HCW, and timing of smell loss relative to SARS-CoV-2 test positivity. SARS-CoV-2 was identified in 17 (3.6%) of 473 HCW. HCW with SARS-CoV-2 infection were more likely to report smell loss than SARS-CoV-2-negative HCW on both the at-home assessment and the screening questionnaire (9/17, 53% vs 105/456, 23%, P <.01). 6/9 (67%) of SARS-CoV-2-positive HCW reporting smell loss reported smell loss prior to having a positive SARS-CoV-2 test, and smell loss was reported a median of two days before testing positive. Neurological symptoms were reported more frequently among SARS-CoV-2-positive HCW who reported smell loss compared to those without smell loss (9/9, 100% vs 3/8, 38%, P <.01). Conclusions: In this prospective study of HCW, self-reported changes in smell using two different measures were predictive of SARS-CoV-2 infection. Smell loss frequently preceded a positive test and was associated with neurological symptoms. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
28. Feasibility, Acceptability, and Adoption of Digital Fingerprinting During Contact Investigation for Tuberculosis in Kampala, Uganda: A Parallel-Convergent Mixed-Methods Analysis (Preprint)
- Author
-
White, Elizabeth B, primary, Meyer, Amanda J, additional, Ggita, Joseph M, additional, Babirye, Diana, additional, Mark, David, additional, Ayakaka, Irene, additional, Haberer, Jessica E, additional, Katamba, Achilles, additional, Armstrong-Hough, Mari, additional, and Davis, John Lucian, additional
- Published
- 2018
- Full Text
- View/download PDF
29. Feasibility, acceptability, and adoption of fingerprint scanning during contact investigation for tuberculosis in Kampala, Uganda: A parallel-convergent, mixed-methods analysis
- Author
-
White, Elizabeth B, primary, Meyer, Amanda J, additional, Ggita, Joseph M, additional, Babirye, Diana, additional, Mark, David, additional, Ayakaka, Irene, additional, Haberer, Jessica E, additional, Katamba, Achilles, additional, Armstrong-Hough, Mari, additional, and Davis, J. Lucian, additional
- Published
- 2018
- Full Text
- View/download PDF
30. The History Professional.
- Author
-
Guterman, Benjamin and White, Elizabeth B.
- Subjects
WAR crimes ,WOMEN historians - Abstract
The article presents an interview with American historian Elizabeth B. White on topics including her academic interests, career at the U.S. Department of Justice's Office of Special Investigations, and the challenges in prosecuting cases related to the Nazis.
- Published
- 2016
31. Les rivalités franco-anglaises et l'élaboration de l'unité italienne, 1789-1849 Stefan-Pascal Luca
- Author
-
White, Elizabeth B.
- Published
- 1943
32. Multiple Transmission Chains within COVID-19 Cluster, Connecticut, USA, 20201.
- Author
-
Bart, Stephen M., Flaherty, Eileen, Alpert, Tara, Carlson, Sherry, Fasulo, Lisa, Earnest, Rebecca, White, Elizabeth B., Dickens, Noel, Brito, Anderson F., Grubaugh, Nathan D., Hadler, James L., and Sosa, Lynn E.
- Subjects
- *
COVID-19 , *SARS-CoV-2 , *PHYSICAL fitness centers , *RESPIRATORY infections - Abstract
In fall 2020, a coronavirus disease cluster comprising 16 cases occurred in Connecticut, USA. Epidemiologic and genomic evidence supported transmission among persons at a school and fitness center but not a workplace. The multiple transmission chains identified within this cluster highlight the necessity of a combined investigatory approach. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
33. Cluster of Influenza A(H5) Cases Associated with Poultry Exposure at Two Facilities - Colorado, July 2024.
- Author
-
Drehoff CC, White EB, Frutos AM, Stringer G, Burakoff A, Comstock N, Cronquist A, Alden N, Armistead I, Kohnen A, Ratnabalasuriar R, Travanty EA, Matzinger SR, Rossheim A, Wellbrock A, Pagano HP, Wang D, Singleton J, Sutter RA, Davis CT, Kniss K, Ellington S, Kirby MK, Reed C, and Herlihy R
- Subjects
- Animals, Humans, Colorado epidemiology, Adult, Male, Middle Aged, Female, Young Adult, Poultry, Influenza, Human epidemiology, Occupational Exposure adverse effects, Influenza in Birds epidemiology, Influenza A Virus, H5N1 Subtype isolation & purification
- Abstract
Persons who work in close contact with dairy cattle and poultry that are infected with highly pathogenic avian influenza (HPAI) A(H5N1) virus are at increased risk for infection. In July 2024, the Colorado Department of Public Health & Environment responded to two poultry facilities with HPAI A(H5N1) virus detections in poultry. Across the two facilities, 663 workers assisting with poultry depopulation (i.e., euthanasia) received screening for illness; 109 (16.4%) reported symptoms and consented to testing. Among those who received testing, nine (8.3%) received a positive influenza A(H5) virus test result, and 19 (17.4%) received a positive SARS-CoV-2 test result. All nine workers who received positive influenza A(H5) test results had conjunctivitis, experienced mild illness, and received oseltamivir. This poultry exposure-associated cluster of human cases of influenza A(H5) is the first reported in the United States. The identification of these cases highlights the ongoing risk to persons who work in close contact with infected animals. Early response to each facility using multidisciplinary, multilingual teams facilitated case-finding, worker screening, and treatment. As the prevalence of HPAI A(H5N1) virus clade 2.3.4.4b genotype B3.13 increases, U.S. public health agencies should prepare to rapidly investigate and respond to illness in agricultural workers, including workers with limited access to health care., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Radhika Ratnabalasuriar reports receipt of per diem payment as an emergency medicine physician from Rocky Mountain Regional VA Medical Center, Intermountain Health Saint Joseph Hospital, and Colorado Kaiser Permanente Group. Emily A. Travanty reports serving as the Colorado Department of Public Health & Environment Institutional Review Board chair and community public health membership on the University of Colorado–Anschutz Medical Campus Institutional Biosafety Committee. Rachel Herlihy reports receipt of sponsorship for travel to annual and working meetings from the Council of State and Territorial Epidemiologists and the Association of Public Health Laboratories. No other potential conflicts of interest were disclosed.
- Published
- 2024
- Full Text
- View/download PDF
34. High Influenza Incidence and Disease Severity Among Children and Adolescents Aged <18 Years - United States, 2022-23 Season.
- Author
-
White EB, O'Halloran A, Sundaresan D, Gilmer M, Threlkel R, Colón A, Tastad K, Chai SJ, Alden NB, Yousey-Hindes K, Openo KP, Ryan PA, Kim S, Lynfield R, Spina N, Tesini BL, Martinez M, Schmidt Z, Sutton M, Talbot HK, Hill M, Biggerstaff M, Budd A, Garg S, Reed C, Iuliano AD, and Bozio CH
- Subjects
- Adolescent, Child, Humans, Infant, COVID-19 epidemiology, Hospitalization, Incidence, Pandemics, Seasons, United States epidemiology, Influenza Vaccines, Influenza, Human prevention & control, Patient Acuity
- Abstract
During the 2022-23 influenza season, early increases in influenza activity, co-circulation of influenza with other respiratory viruses, and high influenza-associated hospitalization rates, particularly among children and adolescents, were observed. This report describes the 2022-23 influenza season among children and adolescents aged <18 years, including the seasonal severity assessment; estimates of U.S. influenza-associated medical visits, hospitalizations, and deaths; and characteristics of influenza-associated hospitalizations. The 2022-23 influenza season had high severity among children and adolescents compared with thresholds based on previous seasons' influenza-associated outpatient visits, hospitalization rates, and deaths. Nationally, the incidences of influenza-associated outpatient visits and hospitalization for the 2022-23 season were similar for children aged <5 years and higher for children and adolescents aged 5-17 years compared with previous seasons. Peak influenza-associated outpatient and hospitalization activity occurred in late November and early December. Among children and adolescents hospitalized with influenza during the 2022-23 season in hospitals participating in the Influenza Hospitalization Surveillance Network, a lower proportion were vaccinated (18.3%) compared with previous seasons (35.8%-41.8%). Early influenza circulation, before many children and adolescents had been vaccinated, might have contributed to the high hospitalization rates during the 2022-23 season. Among symptomatic hospitalized patients, receipt of influenza antiviral treatment (64.9%) was lower than during pre-COVID-19 pandemic seasons (80.8%-87.1%). CDC recommends that all persons aged ≥6 months without contraindications should receive the annual influenza vaccine, ideally by the end of October., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Sue Kim reports institutional support from the Michigan Department of Health & Human Services and the Council of State and Territorial Epidemiologists (CSTE). Ruth Lynfield is a member of CSTE and serves on the program committee for ID Week and is an associate editor for the American Academy of Pediatrics’ (AAP) Red Book (for which she donated the received fee to the Minnesota Department of Health) and is an executive officer of CSTE and the National Foundation for Infectious Diseases (NFID). She receives support for attending meetings of CSTE, NFID, the Infectious Diseases Society of America, and AAP. Kimberly Yousey-Hindes reports receipt of an honorarium for delivering an invited lecture at Western Connecticut State University in October 2020, and receipt of support for travel to the International Influenza Assessor Training by CSTE in January 2023. No other potential conflicts of interest were disclosed.
- Published
- 2023
- Full Text
- View/download PDF
35. Early and Increased Influenza Activity Among Children - Tennessee, 2022-23 Influenza Season.
- Author
-
Thomas CM, White EB, Kojima N, Fill MA, Hanna S, Jones TF, Newhouse CN, Orejuela K, Roth E, Winders S, Chandler DR, Grijalva CG, Schaffner W, Schmitz JE, DaSilva J, Kirby MK, Mellis AM, Rolfes MA, Sumner KM, Flannery B, Talbot HK, and Dunn JR
- Subjects
- Adult, Child, Humans, Infant, Seasons, Tennessee epidemiology, Influenza B virus genetics, Vaccination, Influenza, Human prevention & control, Influenza Vaccines
- Abstract
Influenza seasons typically begin in October and peak between December and February (1); however, the 2022-23 influenza season in Tennessee began in late September and was characterized by high pediatric hospitalization rates during November. This report describes a field investigation conducted in Tennessee during November 2022, following reports of increasing influenza hospitalizations. Data from surveillance networks, patient surveys, and whole genome sequencing of influenza virus specimens were analyzed to assess influenza activity and secondary illness risk. Influenza activity increased earlier than usual among all age groups, and rates of influenza-associated hospitalization among children were high in November, reaching 12.6 per 100,000 in children aged <5 years, comparable to peak levels typically seen in high-severity seasons. Circulating influenza viruses were genetically similar to vaccine components. Among persons who received testing for influenza at outpatient clinics, children were twice as likely to receive a positive influenza test result as were adults. Among household contacts exposed to someone with influenza, children were more than twice as likely to become ill compared with adults. As the influenza season continues, it is important for all persons, especially those at higher risk for severe disease, to protect themselves from influenza. To prevent influenza and severe influenza complications, all persons aged ≥6 months should get vaccinated, avoid contact with ill persons, and take influenza antivirals if recommended and prescribed., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Noah Kojima reports receipt of consulting fees from Curative. Mary-Margaret A. Fill reports support from the Council of State and Territorial Epidemiologists (CSTE) to attend the CSTE annual meeting, and from Johns Hopkins University to attend the Johns Hopkins Center for Health Security Emerging Leaders in Biosecurity Summer Research Symposium; service as an external member on the University of Tennessee’s One Health Initiative Board; and participation as CSTE representative to the Advisory Committee on Immunization Practices Adult Immunization Schedules and General Best Practices work groups. Carlos G. Grijalva reports institutional support from the National Institute for Allergy and Infectious Diseases, National Institutes of Health (NIH); grant support from NIH, the Agency for Healthcare Research and Quality, the Food and Drug Administration, and Campbell Alliance/Syneos Health; consulting fees from Merck; and advisory services to Merck. William Schaffner reports serving as the medical director of the National Foundation for Infectious Diseases. Jonathan E. Schmitz reports federal, Roche, and Quantum Material Correlation grant support; consulting fees from Gene Capture, Inc.; and honoraria from Pfizer. No other potential conflicts of interest were disclosed.
- Published
- 2023
- Full Text
- View/download PDF
36. Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons - 43 U.S. Jurisdictions, July 31-October 1, 2022.
- Author
-
Payne AB, Ray LC, Cole MM, Canning M, Houck K, Shah HJ, Farrar JL, Lewis NM, Fothergill A, White EB, Feldstein LR, Roper LE, Lee F, Kriss JL, Sims E, Spicknall IH, Nakazawa Y, Gundlapalli AV, Shimabukuro T, Cohen AL, Honein MA, Mermin J, and Payne DC
- Subjects
- Humans, Male, Homosexuality, Male, United States epidemiology, United States Food and Drug Administration, Smallpox Vaccine administration & dosage, Sexual and Gender Minorities, Mpox (monkeypox) prevention & control
- Abstract
As of October 28, 2022, a total of 28,244* monkeypox (mpox) cases have been reported in the United States during an outbreak that has disproportionately affected gay, bisexual, and other men who have sex with men (MSM) (1). JYNNEOS vaccine (Modified Vaccinia Ankara vaccine, Bavarian Nordic), administered subcutaneously as a 2-dose (0.5 mL per dose) series (with doses administered 4 weeks apart), was approved by the Food and Drug Administration (FDA) in 2019 to prevent smallpox and mpox disease (2); an FDA Emergency Use Authorization issued on August 9, 2022, authorized intradermal administration of 0.1 mL per dose, increasing the number of persons who could be vaccinated with the available vaccine supply
† (3). A previous comparison of mpox incidence during July 31-September 3, 2022, among unvaccinated, but vaccine-eligible men aged 18-49 years and those who had received ≥1 JYNNEOS vaccine dose in 32 U.S. jurisdictions, found that incidence among unvaccinated persons was 14 times that among vaccinated persons (95% CI = 5.0-41.0) (4). During September 4-October 1, 2022, a total of 205,504 persons received JYNNEOS vaccine dose 2 in the United States.§ To further examine mpox incidence among persons who were unvaccinated and those who had received either 1 or 2 JYNNEOS doses, investigators analyzed data on 9,544 reported mpox cases among men¶ aged 18-49 years during July 31-October 1, 2022, from 43 U.S. jurisdictions,** by vaccination status. During this study period, mpox incidence (cases per 100,000 population at risk) among unvaccinated persons was 7.4 (95% CI = 6.0-9.1) times that among persons who received only 1 dose of JYNNEOS vaccine ≥14 days earlier and 9.6 (95% CI = 6.9-13.2) times that among persons who received dose 2 ≥14 days earlier. The observed distribution of subcutaneous and intradermal routes of administration of dose 1 among vaccinated persons with mpox was not different from the expected distribution. This report provides additional data suggesting JYNNEOS vaccine provides protection against mpox, irrespective of whether the vaccine is administered intradermally or subcutaneously. The degree and durability of such protection remains unclear. Persons eligible for mpox vaccination should receive the complete 2-dose series to optimize strength of protection†† (5)., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.- Published
- 2022
- Full Text
- View/download PDF
37. Tracking Smell Loss to Identify Healthcare Workers with SARS-CoV-2 Infection.
- Author
-
Weiss JJ, Attuquayefio TN, White EB, Li F, Herz RS, White TL, Campbell M, Geng B, Datta R, Wyllie AL, Grubaugh ND, Casanovas-Massana A, Muenker MC, Handoko R, Iwasaki A, Martinello RA, Ko AI, Small DM, and Farhadian SF
- Abstract
Background: Healthcare workers (HCW) treating COVID-19 patients are at high risk for infection and may also spread infection through their contact with vulnerable patients. Smell loss has been associated with SARS-CoV-2 infection, but it is unknown whether monitoring for smell loss can be used to identify asymptomatic infection among high risk individuals, like HCW., Methods: We performed a prospective cohort study, tracking 473 HCW across three months to determine if smell loss could predict SARS-CoV-2 infection in this high-risk group. HCW subjects completed a longitudinal, novel behavioral at-home assessment of smell function with household items, as well as detailed symptom surveys that included a parosmia screening questionnaire, and RT-qPCR testing to identify SARS-CoV-2 infection., Results: SARS-CoV-2 was identified in 17 (3.6%) of 473 HCW. Among the 17 infected HCW, 53% reported smell loss, and were more likely to report smell loss than COVID-negative HCW on both the at-home assessment and the screening questionnaire (P < .01). 67% reported smell loss prior to having a positive SARS-CoV-2 test, and smell loss was reported a median of two days before testing positive. Neurological symptoms were reported more frequently among COVID-positive HCW who reported smell loss (P < .01)., Conclusions: In this prospective study of HCW, self-reported changes in smell using two different measures were predictive of COVID-19 infection. Smell loss frequently preceded a positive test and was associated with neurological symptoms.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.